A drug strategy targeting heat shock protein 90 to combat metastatic, p53-mutant ovarian cancer. GANNET53 (Ganetespib in metastatic, p53-mutant ovarian cancer) is a FP7 research project funded by the European Commission. The project started in October 2013 and aims at improving the prognosis and quality of life of p53-mutant ovarian cancer patients. Who are we? GANNET53 is a group of passionate collaborators, click here to find out more about them. What we do? Learn more about our clinical trials and translational research...

    This project has received funding from the European Union’s Seventh Framework Programme for research,
technological development and demonstration under grant agreement no 602602.
   
© 2013 all rights reserved / LEGAL INFORMATION/ CONTACT